Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $175.00
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) had its price target lifted by equities research analysts at Benchmark from $160.00 to $175.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Benchmark’s target price indicates a potential upside of 5.08% from the company’s previous close. […]
More Stories
7 Best TextNow Alternatives for Free Calling in 2026
Free calling apps like TextNow are being widely used today for smooth global communication without needing extra hardware and software....
Trump Says US Has Seized Oil Tanker Off Coast of Venezuela
By Jack Phillips President Donald Trump said on Dec. 10 that the United States seized an oil tanker off the...
Land Along Southern Border Is Transferred to Navy to Become Part of ‘National Defense Area’
By Jacob Burg The Trump administration said on Dec. 10 that it would transfer roughly 760 acres of public land...
We’ve Just Seen the Best Quarter in 3 Years (In Revenues) or 4 Years (Earnings)
By Louis Navellier I wrote this last weekend aboard the forty-fourth Forbes Cruise for Investors, where there was a high...
New Bipartisan Bills Aim to Raise Penalties for Online Child Abuse, Sextortion
By Savannah Hulsey Pointer Lawmakers announced on Dec. 9 three new bipartisan bills to address online violence and sexual abuse...
British Soldier Killed in Ukraine Watching Training Exercise
By Jill McLaughlin A British soldier was killed in Ukraine on Dec. 9 while watching a training exercise, the UK...